当前位置: X-MOL 学术Radiother. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Radiotherapy after primary CHEMotherapy (RAPCHEM): Practice variation in a Dutch registration study (BOOG 2010-03)
Radiotherapy and Oncology ( IF 4.9 ) Pub Date : 2020-04-01 , DOI: 10.1016/j.radonc.2020.01.018
Liesbeth J Boersma 1 , Janneke Verloop 2 , Adri C Voogd 3 , Paula H M Elkhuizen 4 , Ruud Houben 1 , A Elise van Leeuwen 5 , Sabine Linn 6 , Linda de Munck 2 , Ruud Pijnappel 7 , Luc Strobbe 8 , Thijs van Dalen 9 , Jelle Wesseling 10 , Philip Poortmans 11
Affiliation  

BACKGROUND We conducted a prospective cohort study in the Netherlands (RAPCHEM: NCT01279304, BOOG 2010-03) in breast cancer (BC) patients treated with primary systemic therapy (PST), followed by surgery and post-operative radiation therapy (RT) according to a predefined consensus-based study-guideline (SG). The aim of the current analysis is to evaluate adherence to the SG. METHODS From January 2011 to January 2015, patients with cT1-2N1 BC treated in 17 Dutch RT Centres were included. Patients with four or more suspicious nodes at imaging were excluded. SG recommended whole breast RT for patients treated with breast conserving therapy. SG on loco(-regional) RT were defined for three risk groups based on the ypN status: (1) ypN0 (low-risk): RT breast and no RT after mastectomy; (2) ypN1 (intermediate-risk): RT breast or chest wall; (3) ypN2 (high-risk): RT breast or chest wall, including regional lymph nodes. RESULTS We included 848 patients: 292 in the low-risk group; 374 in the intermediate-risk group; 182 in the high-risk group. Overall, 64% of the patients was treated according to the SG; 11% received less RT than the predefined target volumes and 25% received more extensive RT than according to the SG. The largest variation was seen in the intermediate risk group, where only 54% was treated according to the SG. CONCLUSION Substantial deviation from the SG for post-operative RT was observed after PST, especially in patients with an intermediate-risk. Future analyses will evaluate outcome of these patients in relation to risk factors and the actual RT given.

中文翻译:

主要化疗后的放射治疗 (RAPCHEM):荷兰注册研究中的实践变化 (BOOG 2010-03)

背景 我们在荷兰进行了一项前瞻性队列研究(RAPCHEM:NCT01279304,BOOG 2010-03),研究对象为接受初级全身治疗 (PST)、随后接受手术和术后放射治疗 (RT) 的乳腺癌 (BC) 患者。预定义的基于共识的研究指南 (SG)。当前分析的目的是评估对 SG 的依从性。方法 2011 年 1 月至 2015 年 1 月,在 17 个荷兰 RT 中心接受治疗的 cT1-2N1 BC 患者被纳入。排除成像中有四个或更多可疑淋巴结的患者。SG 建议对接受保乳治疗的患者进行全乳放疗。根据 ypN 状态为三个风险组定义了局部(区域)放疗的 SG:(1) ypN0(低风险):乳房切除术后放疗和无放疗;(2) ypN1(中危):放疗乳房或胸壁;(3) ypN2(高危):放疗乳房或胸壁,包括区域淋巴结。结果 我们纳入了 848 名患者:292 名在低风险组;中危组374人;高危组182人。总体而言,64% 的患者根据 SG 进行治疗;11% 的人接受的 RT 比预定义的目标量少,25% 的人接受的 RT 比根据 SG 更广泛。中度风险组的变异最大,根据 SG,只有 54% 的患者接受了治疗。结论 PST 后观察到术后放疗与 SG 的显着偏差,尤其是在中危患者中。未来的分析将评估这些患者与风险因素和实际放疗相关的结果。低危组292人;中危组374人;高危组182人。总体而言,64% 的患者根据 SG 进行治疗;11% 的人接受的 RT 比预定义的目标量少,25% 的人接受的 RT 比根据 SG 更广泛。中度风险组的变异最大,根据 SG,只有 54% 的患者接受了治疗。结论 PST 后观察到术后放疗与 SG 的显着偏差,尤其是在中危患者中。未来的分析将评估这些患者与风险因素和实际放疗相关的结果。低危组292人;中危组374人;高危组182人。总体而言,64% 的患者根据 SG 进行治疗;11% 的人接受的 RT 比预定义的目标量少,25% 的人接受的 RT 比根据 SG 更广泛。中度风险组的变异最大,根据 SG,只有 54% 的患者接受了治疗。结论 PST 后观察到术后放疗与 SG 的显着偏差,尤其是在中危患者中。未来的分析将评估这些患者与风险因素和实际放疗相关的结果。11% 的人接受的 RT 比预定义的目标量少,25% 的人接受的 RT 比根据 SG 更广泛。中度风险组的变异最大,根据 SG,只有 54% 的患者接受了治疗。结论 PST 后观察到术后放疗与 SG 的显着偏差,尤其是在中危患者中。未来的分析将评估这些患者与风险因素和实际放疗相关的结果。11% 的人接受的 RT 比预定义的目标量少,25% 的人接受的 RT 比根据 SG 更广泛。中度风险组的变异最大,根据 SG,只有 54% 的患者接受了治疗。结论 PST 后观察到术后放疗与 SG 的显着偏差,尤其是在中危患者中。未来的分析将评估这些患者与风险因素和实际放疗相关的结果。
更新日期:2020-04-01
down
wechat
bug